Aggregate complexes of HIV-1 induced by multimeric antibodies

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Stieh, Daniel J ^a,b   King, Deborah F ^c   Klein, Katja ^c   Liu, Pinghuang ^d,i   Shen, Xiaoying ^d   Hwang, Kwan K ^d   Ferrari, Guido ^d   Montefiori, David C ^d   Haynes, Barton ^d   Pitisuttithum, Punnee ^e   Kaewkungwal, Jaranit ^e   Nitayaphan, Sorachai ^f   Rerks Ngarm, Supachai ^g   Michael, Nelson L ^h   Robb, Merlin L ^h   Kim, Jerome H ^h   Denny, Thomas N ^d   Tomaras, Georgia D ^d   Shattock, Robin J ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Aggregation; HIV 1; Immunoglobulin A; Mucosal immunity

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CROSS LINKING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGHT SCATTERING; NONHUMAN; OPSONIZATION; PROTEIN AGGREGATION; STOICHIOMETRY; VIRAL AGGREGATION; VIRAL PHENOMENA AND FUNCTIONS; VIRION; VIRUS PARTICLE; IMMUNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

EID: 84907999584     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0078-8     Document Type: Article

References (46)

1. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5(3):233-236. 10.1038/ni0304-233.
2. Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011, 1(1):a007278. 10.1101/cshperspect.a007278.
3. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J. Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 2008, 5(4):e81. 10.1371/journal.pmed.0050081.
4. Kraehenbuhl JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev 1992, 72(4):853-879.
5. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011, 4(6):603-611. 10.1038/mi.2011.41.
6. Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z, McGhee JR, Mestecky J. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A 1987, 84(8):2449-2453. 10.1073/pnas.84.8.2449.
7. Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS 1995, 103(1):1-19. 10.1111/j.1699-0463.1995.tb01073.x.
8. Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. Nat Rev Micro 2010, 8(9):656-667. 10.1038/nrmicro2384.
9. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996, 104(3):538-542. 10.1046/j.1365-2249.1996.36742.x.
10. Mestecky J, Russell MW. IgA subclasses. Monogr Allergy 1986, 19:277-301.
11. Hope TJ. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med 2011, 17(10):1195-1197. 10.1038/nm.2528.
12. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003, 1(1):25-34. 10.1038/nrmicro729.
13. Tomaras GD, Haynes BF. Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS 2010, 5(5):421-427. 10.1097/COH.0b013e32833d2d45.
14. Che Z, Olson NH, Leippe D, Lee WM, Mosser AG, Rueckert RR, Baker TS, Smith TJ. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol 1998, 72(6):4610-4622.
15. Colonno RJ, Callahan PL, Leippe DM, Rueckert RR, Tomassini JE. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 1989, 63(1):36-42.
16. Brioen P, Dekegel D, Boeye A. Neutralization of poliovirus by antibody-mediated polymerization. Virology 1983, 127(2):463-468. 10.1016/0042-6822(83)90159-9.
17. Semler BL, Ehrenfeld E: Molecular Aspects Of Picornavirus Infection And Detection. In Washington, D.C.: American Society for Microbiology; 1989..
18. Hassan PA, Rana S, Verma G: Making sense of brownian motion: colloid characterization by dynamic light scattering.Langmuir 2014, Epub..
19. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope A, Cai C, Giemza R, Jeffs SA, Manoussaka M, Cole T, Cranage MP, Shattock RJ, Lacey CJ. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One 2011, 6(9):e25165. 10.1371/journal.pone.0025165.
20. Stieh DJ, Phillips JL, Rogers PM, King DF, Cianci GC, Jeffs SA, Gnanakaran S, Shattock RJ. Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Retrovirology 2013, 10:33. 10.1186/1742-4690-10-33.
21. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Sowder RC, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 2006, 80(18):9039-9052. 10.1128/JVI.01013-06.
22. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72(10):7992-8001.
23. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 2010, 6(12):e1001249. 10.1371/journal.ppat.1001249.
24. Trubey CM, Chertova E, Coren LV, Hilburn JM, Hixson CV, Nagashima K, Lifson JD, Ott DE. Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J Virol 2003, 77(23):12699-12709. 10.1128/JVI.77.23.12699-12709.2003.
25. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220. 10.1056/NEJMoa0908492.
26. Salmon-Ceron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999, 15(7):633-645. 10.1089/088922299310935.
27. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012, 206(3):431-441. 10.1093/infdis/jis367.
28. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013, 110(22):9019-9024. 10.1073/pnas.1301456110.
29. Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis VR, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD. Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. J Virol 2013, 87(14):7828-7836. 10.1128/JVI.02737-12.
30. Kerr MA. The structure and function of human IgA. Biochem J 1990, 271(2):285-296.
31. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012, 28(11):1444-1457. 10.1089/aid.2012.0103.
32. Bonsignori M1, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012, 86(21):11521-11532. 10.1128/JVI.01023-12.
33. Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6(5):e1000908. 10.1371/journal.ppat.1000908.
34. Mouquet H1, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467(7315):591-595. 10.1038/nature09385.
35. Thomas AA, Vrijsen R, Boeye A. Relationship between poliovirus neutralization and aggregation. J Virol 1986, 59(2):479-485.
36. Bonner A, Furtado PB, Almogren A, Kerr MA, Perkins SJ. Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy. J Immunol 2008, 180(2):1008-1018. 10.4049/jimmunol.180.2.1008.
37. Matyas GR, Beck Z, Karasavvas N, Alving CR. Lipid binding properties of 4E10, 2 F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009, 1788(3):660-665. 10.1016/j.bbamem.2008.11.015.
38. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol 2011, 85(16):8217-8226. 10.1128/JVI.00756-11.
39. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, Chen B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2009, 106(48):20234-20239. 10.1073/pnas.0908713106.
40. Muranyi W, Malkusch S, Muller B, Heilemann M, Krausslich HG. Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail. PLoS Pathog 2013, 9(2):e1003198. 10.1371/journal.ppat.1003198.
41. Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, et al. Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. J Virol 2013, 87(3):1554-1568. 10.1128/JVI.00718-12.
42. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366(14):1275-1286. 10.1056/NEJMoa1113425.
43. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013, 27(9):F13-F20. 10.1097/QAD.0b013e328360eac6.
44. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000, 74(12):5577-5586. 10.1128/JVI.74.12.5577-5586.2000.
45. Arthur LO, Bess JW, Chertova EN, Rossio JL, Esser MT, Benveniste RE, Henderson LE, Lifson JD. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses 1998, 14(Suppl 3):S311-S319.
46. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008, 82(24):12449-12463. 10.1128/JVI.01708-08.